Screening und Prävention der chronischen Virushepatitis

Chronische Virushepatitiden, insbesondere durch Hepatitis-B- und -C-Viren, gehören weltweit zu den häufigsten Ursachen der Leberzirrhose und des hepatozellulären Karzinoms (HCC). Trotz wirksamer Therapieoptionen bleiben viele Infektionen unerkannt. Durch ein Screening können chronische Infektionen frühzeitig diagnostiziert und einer Therapie zugeführt werden. Dieser Beitrag fasst aktuelle Empfehlungen zur Prävention und Früherkennung zusammen.

Abstract

Chronic viral hepatitis, particularly chronic hepatitis B and C, is among the leading global causes of liver cirrhosis and hepatocellular carcinoma (HCC). Despite effective treatment options such as virus suppressive nucleos(t)ide analogues for HBV and curative direct acting antiviral therapies for HCV, many infections remain undetected. The WHO aims to eliminate hepatitis B and C as public health threats by 2030, targeting a 90% reduction in new infections and a 65% reduction in deaths. Germany supports these objectives through its BIS 2030 strategy, which emphasizes prevention, identification of at-risk groups, education, and treatment. A central component is screening to diagnose chronic infections early and initiate therapy promptly. This article summarizes practical current recommendations for the prevention and early detection of chronic viral hepatitis, with a particular focus on hepatitis B and hepatitis C, including complementary aspects regarding hepatitis D and hepatitis E in immunocompromised individuals.

Schlüsselwörter

Prävention - Hepatitis B - Hepatitis C - Hepatitis D - Hepatitis E

Keywords

Prevention - Hepatitis B - Hepatitis C - Hepatitis D - Hepatitis E

• Literatur

• 1 Cornberg M, Sandmann L, Protzer U. et al. S3-Leitlinie der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) zur Prophylaxe, Diagnostik und Therapie der Hepatitis-B-Virusinfektion. AWMF-Register-Nr. 021–11. Z Gastroenterol 2021; 59: 691-776
• 2 Sarrazin C, Zimmermann T, Berg T. et al. Prophylaxe, Diagnostik und Therapie der Hepatitis-C-Virus(HCV)-Infektion. Z Gastroenterol 2020; 58: 1110-1131
• 3 Sandmann L, Berg T, Deterding K. et al. Addendum „Antivirale Therapie der chronischen Hepatitis-D-Virusinfektion“ zur S3-Leitlinie „Prophylaxe, Diagnostik und Therapie der Hepatitis-B- Virusinfektion“ der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS). 2023 Zugriff am 14. Juli 2025 unter: www.dgvs.de/wp-content/uploads/2023/07/Addendum-HDV_11.07.23.pdf
• 4 European Association for the Study of the Liver. EASL Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol 2025;
• 5 European Association for the Study of the Liver. EASL Clinical Practice Guidelines on hepatitis delta virus. J Hepatol 2023; 79: 433-460
• 6 European Association for the Study of the Liver. Electronic address: [e-mail], European Association for the Study of the Liver: EASL Clinical Practice Guidelines on hepatitis E virus infection. J Hepatol 2018; 68: 1256-1271
• 7 Bätz O, Petroff D, Jedrysiak K. et al. Successful hepatitis B and C screening in the health check-up in the German primary care setting. JHEP Rep 2024; 6: 101122
• 8 World Health Organization. Global hepatitis report 2024: action for access in low- and middle-income countries. 2024 Zugriff am 16. März 2025 unter: www.who.int/publications/i/item/9789240091672
• 9 Wolffram I, Petroff D, Bätz O. et al. Prevalence of elevated ALT values, HBsAg, and anti-HCV in the primary care setting and evaluation of guideline defined hepatitis risk scenarios. J Hepatol 2015; 62: 1256-1264
• 10 Polaris Observatory Collaborators. Global prevalence, cascade of care, and prophylaxis coverage of hepatitis B in 2022: a modelling study. Lancet Gastroenterol Hepatol 2023; 8: 879-907
• 11 Hüppe D, Serfert Y, Cornberg M. et al. Significant increase in newly diagnosed hepatitis B and C cases in Germany due to screening. Z Gastroenterol 2025; 63: 31-38
• 12 Hüppe D, Wedemeyer H, Cornberg M. Population-based screening works: Effect of integrating screening for hepatitis B and C into the general health check-up in Germany. J Hepatol 2023;
• 13 Lazarus JV, Picchio CA, Byrne CJ. et al. A Global Systematic Review of Hepatitis C Elimination Efforts through Micro-Elimination. Semin Liver Dis 2022; 42: 159-172
• 14 Wedemeyer H, Tergast TL, Lazarus JV. et al. Securing Wider EU Commitment to the Elimination of HCV. Liver Int 2023; 43 (02) 276-291
• 15 Eckman MH, Ward JW, Sherman KE. Cost Effectiveness of Universal Screening for Hepatitis C Virus Infection in the Era of Direct-Acting, Pangenotypic Treatment Regimens. Clin Gastroenterol Hepatol 2019; 17: 930-939.e9
• 16 Herta T, Joachim-Richter A, Petroff D. et al. Successful Amendment of an Existing Hepatitis B Screening Programme by a Guideline Recommended Hepatitis D Screening in the Primary Care Setting. Aliment Pharmacol Ther 2025; 61: 651-657
• 17 Santen DK, Lodi S, Dietze P. et al. Comprehensive needle and syringe program and opioid agonist therapy reduce HIV and hepatitis c virus acquisition among people who inject drugs in different settings: A pooled analysis of emulated trials. Addiction 2023; 118: 1116-1126
• 18 Artenie A, Trickey A, Looker KJ. et al. Global, regional, and national estimates of hepatitis C virus (HCV) infection incidence among people who inject drugs and number of new annual HCV infections attributable to injecting drug use: a multi-stage analysis. Lancet Gastroenterol Hepatol 2025; 10: 315-331
• 19 Boerekamps A, van den Berk GE, Lauw FN. et al. Declining Hepatitis C Virus (HCV) Incidence in Dutch Human Immunodeficiency Virus-Positive Men Who Have Sex With Men After Unrestricted Access to HCV Therapy. Clin Infect Dis 2018; 66: 1360-1365
• 20 Cornberg M, Wedemeyer H. Early treatment of acute or recently acquired hepatitis C: An important tool on the path to HCV elimination!. Hepatology 2025; 81: 771-773